Limited Liability Company "Research Center Eco-Safety"
Welcome,         Profile    Billing    Logout  
 0 Trials 
7 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Vasilyuk, Vasiliy
NCT05216497: Efficacy and Safety of Ingavirin®, 90 mg Capsules in Patients With COVID-19

Completed
3
233
RoW
Ingavirin®, 90 mg capsules, Placebo
Valenta Pharm JSC
COVID-19
01/22
04/22
RSV OA=ADJ=012, NCT06534892: An Extension and Crossover Vaccination Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus Given to Adults 60 Years of Age and Above Who Participated in RSV OA=ADJ-006 Study

Recruiting
3
12000
Europe, Canada, Japan, US, RoW
RSVPreF3 OA vaccine
GlaxoSmithKline
Respiratory Syncytial Virus Infections
09/26
09/26
NCT05294250: Study of the Effect of Food Intake on the Bioavailability of XC8 10 mg Film-coated Tablets

Completed
1
24
RoW
XC8
Valenta Pharm JSC
Healthy
02/22
02/22
NCT05295121: Study of the Effect of Food Intake on the Bioavailability of XC221 100 mg Tablets

Completed
1
24
RoW
XC221 100 mg tablets
Valenta Pharm JSC
Healthy
02/22
03/22
NCT06315387: Safety, Tolerability and Pharmacokinetics of 4-MUST, Tablets, 128 mg (Valenta Pharm JSC) During Single and Multiple Oral Administration in Healthy Volunteers

Recruiting
1
42
RoW
4-MUST, 1 tablet, 4-MUST, 2 tablets, 4-MUST, 3 tablets
Valenta Pharm JSC
Cholecystitis
12/24
12/24
NCT05412173: Pharmacokinetics and Bioequivalence of Molnupiravir, 200 mg Capsules and Lagevrio, 200 mg Capsules in Healthy Volunteers

Completed
N/A
37
RoW
Molnupiravir
Valenta Pharm JSC
Viral Infection, COVID-19
05/22
06/22
NCT06096571: Pharmacokinetics and Bioequivalence of Aterixen 100 mg Tablets and Aterixen 100 mg Film-coated Tablets in Healthy Volunteers

Not yet recruiting
N/A
36
RoW
Aterixen
Valenta Pharm JSC
Viral Infection COVID-19
12/24
12/24

Download Options